BioSpace News Archive

SciNeuro Pharmaceuticals is developing novel therapeutics to address major unmet need within CNS diseases. The company is pleased to announce an executive leadership appointment, and update on key pipeline progress milestones.

Walden Biosciences, Inc. today announced that Alex Duncan, Ph.D., Chief Scientific Officer of Walden Biosciences, will give a presentation at the Antibody Engineering and Therapeutic Conference 2022, being held from December 4-8, 2022 in San Diego, CA.

Ginkgo Bioworks Holdings, Inc. today announced that in connection with its transaction with Bayer CropScience LP (“Bayer”) on October 17, 2022, Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of Zymergen Inc. (“Zymergen”) on October 19, 2022.

Syndax Pharmaceuticals, Inc. today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5 , 2022.

STRATA Skin Sciences, Inc. announced the company will present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference being held at the Fontainebleau Miami Beach, Miami, Florida on December 8, 2022.

Novan, Inc., announced that EPI Health, LLC, a fully consolidated subsidiary of the Company, has signed an accounts receivable-backed factoring agreement, to support its operations, with Bay View Funding, a wholly owned subsidiary of Heritage Bank of Commerce.

Reaction Biology Corporation (“Reaction”) today announced that the Company has closed on a definitive agreement for Reaction to acquire Bioassay Labor für biologische Analytik GmbH (“Bioassay”), including its wholly-owned subsidiary, Peptide Specialty Laboratories GmbH (“PSL”), located in Heidelberg, Germany.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A -related epilepsies.

SeaStar Medical Holding Corporation today announced the appointment of Thomas R. Mullen as Vice President of Operations and Product Development.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI.